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A B S T R A C T
Reporting guidelines help improve the reporting of speciﬁc study designs, and clear guidance on the best ap-
proaches for developing guidelines is available. The methodological strength, or validation of guidelines is
however unclear. This article explores what validation of reporting guidelines might involve, and whether this
has been conducted for key reporting guidelines.
1. Introduction
Comprehensive reporting can reduce reporting bias, enable in-
formed decision making in clinical practice, limit duplication of eﬀort
and inform subsequent research [1]. The quality of reporting of re-
search activity continues to be inadequate, presenting readers with
diﬃculties in judging the reliability of research ﬁndings, or how best to
interpret results for individual settings [2,3].
Reporting guidelines have been developed to help improve the re-
porting of speciﬁc study designs. If followed by authors this should
enable users to understand the design, conduct and analysis of the re-
search, to critically appraise and review the ﬁndings and interpret the
conclusions appropriately [4].
A guideline is a checklist, diagram or explicit text which guides
authors in reporting research, and should be developed using explicit
methodology [2]. Many already exist, mostly as checklists, and clear
guidance, including a checklist of recommended steps, for developing
such tools is available [2].
2. Use of guidelines
A search of the websites of ﬁve leading medical and health research
journals (BMJ, Journal of the American Medical Association (JAMA),
Lancet, New England Journal of Medicine (NEJM) and BMC Trials)
identiﬁed the reporting guidelines included in the journals’ instructions
to authors. These journals were purposively sampled as they: are pro-
minent in the publication of a wide range of research topics and study
designs; each publish signiﬁcant volumes of research over a 3-month
period (RCT publication rate, range 1–10 per month; 4–31 per quarter);
and represent a range of impact factors (Range: 2.067 to 79.258).
All ﬁve journals require the use of the CONSORT reporting
guidelines for randomised controlled trial (RCT) manuscripts. For RCTs,
the BMJ also speciﬁcally recommend use of the TIDieR checklist to
ensure accurate and complete reporting of a trial intervention [5]. BMC
Trials, BMJ, JAMA and Lancet promote the use of reporting guidelines
for other study designs and refer authors to the EQUATOR (Enhancing
the QUAlity and Transparency Of health Research) Network database of
reporting guidelines [6].
The EQUATOR Network is an international multidisciplinary group
that promotes transparent and accurate health research reporting
through use of reporting guidelines. The network provides access to a
comprehensive range of such guidelines in a searchable database
(http://www.equator-network.org). However, there is evidence that
simply having reporting guidelines, even with journal endorsement of
their use, is insuﬃcient [7].
The EQUATOR Network takes an inclusive approach and are clear
that there is no indication of methodological strength, or validation of
the guidelines listed. The reporting guidelines for the main study types,
such as CONSORT for RCTs, STROBE for observational studies, and
STARD for diagnostic/prognostic studies, are highlighted on the front
page of the EQUATOR Network website. We decided to explore what
validation of reporting guidelines might involve.
3. Validation
Validation is ‘the action of checking or proving the validity or ac-
curacy of something’ [8] principles already well established in the de-
velopment of health care and research documentation.
In the UK the National Institute for Health and Care Excellence
(NICE) requires validation of guidelines designed to inform decisions in
health, public health and social care (https://www.nice.org.uk/about/
what-we-do/our-programmes/nice-guidance). As a minimum,
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validation comprises stakeholder review, with ﬁeldwork to trial im-
plementation and discussions with service users, with external review
also included if warranted, for example for guidelines in complex or
sensitive areas (https://www.nice.org.uk/process/pmg20/chapter/the-
validation-process-for-draft-guidelines-and-dealing-with-stakeholder-
comments).
A number of initiatives provide standards for the development and
validation of patient reported outcome measures (PROMs) for research
[9–11]. This includes identifying the scope and focus of the measure,
reviewing literature, engaging relevant stakeholders, and consensus
assessment. Guidance for the development of health research reporting
guidelines suggests similar features to those used for PROMs: 1) Lit-
erature review; 2) Delphi process; 3) Identiﬁcation of key items; 4)
Meeting with collaborators; 5) Iterative revision and review; 6) Pilot
testing, all of which are derived from the authors’ comprehensive ex-
perience in the development of reporting guidelines [2]. While there
are many similarities in the proposed activities for the development of
PROMs and reporting guidelines, unlike PROMS, methods of validation
of reporting guidelines are not explicitly mentioned.
In 2016 we conducted a systematic literature search using MEDLINE
to identify validation methods commonly used for PROMs. Search
strategies are provided in Supplementary Document 1. Our pre-deﬁned
inclusion criteria were for studies: focused on PROMs; detailing a va-
lidation method; references other publications regarding validation.
Two authors independently screened the search results against the in-
clusion criteria, identiﬁed 73 relevant papers. Details of the included
papers are provided in Supplementary Document 2. Data on PROM
type, validation method, and if this was noted as a strength or limita-
tion were extracted and a summary of the validation methods identiﬁed
is detailed in Tables 1 and 2.
By far the most common method of validation was use of statistical
testing either as a single validation method or in combination with
other methods. The most common combination was statistical testing in
conjunction with comparison with similar measures. This corresponds
to guidance published in 2011 which indicates that comparison and
correlation with similar, existing measures is critical in the develop-
ment of PROMS [10].
4. Are reporting guidelines validated?
Having established the methods of validation, we went on to see
which had been used in the reporting guidelines highlighted on the
EQUATOR Network homepage.
We conducted a literature search in 2018 to identify papers re-
porting the development of guidelines for the main study types as
highlighted on the EQUATOR network website. Two researchers in-
dependently extracted information about the development and valida-
tion methods reported; disagreements were resolved through discus-
sion. We excluded papers where content analysis was the sole measure
used, as this was not explicitly identiﬁed as a validation activity. The
results are summarised in Table 3.
The methods described within the papers matched the principles
outlined in the guidance for the development of health research re-
porting guidelines [2]. While some guideline developers utilised mul-
tiple components and others were more selective, we believe the
overarching principles remained. In the absence of clear statements, a
pragmatic interpretation would say, for example, that evidence synth-
esis requires a literature review, and having done a literature review, or
convened a stakeholder meeting, it can be supposed that validation
methods were used. Of note here, is that although following the key
principles, this activity is not noted as being ‘validation’. This could
account for why this term is not, used in the context of promoting the
use of reporting guidelines.
5. Discussion
Reporting guidelines, are available for a wide range of health care
research methodologies [6]. Many journals request their use to increase
transparent research reporting, however mandated use is rare, despite
evidence that reporting guidelines can have a positive impact on
completeness of reporting [7,21].
Validation is important to ensure the validity and accuracy of tools
used within the conduct and reporting of research. Whilst the validation
of PROMS is frequently reported, we have identiﬁed that while vali-
dation activities for reporting guidelines do occur, the activities are not
always explicitly reported as such. This may occur because some vali-
dation activities are also part of the development process, for example a
consensus exercise. Reporting of the development of future reporting
guidelines for research, may beneﬁt from clearly identifying the work
undertaken to ensure the accuracy of the guidelines proposed. This
could be within a ‘Validation’ section of a guideline publication or by
simple use of the words ‘validated/validation’ in the context of the
activity being reported. For completeness of reporting, it may also be
appropriate to request use of a development and validation checklist,
for example that provided by Moher et al. {2}, where guideline de-
velopment is reported.
The EQUATOR Network database currently contains around 406
reporting guidelines which cover a variety of research methodologies,
many either specialised or narrow in scope. It is unclear how many of
these included validation activities in their development, and we have
not been able to identify any post development or publication valida-
tion work from our literature search. Ensuring validation activities are
not only undertaken but also clearly reported could add weight to the
value of reporting guidelines for both those promoting their use and
those authoring papers. By understanding what validation looks like,
we would suggest that journals and peer reviewers could be encouraged
to mandate the use of validated checklists.
Despite being included as one of the elements for the development
of health research reporting guidelines, it is surprising that a limited
number of the guideline development papers used pilot testing prior to
publication. Given that reporting guidelines are intended to ensure
transparent reporting across similar research methodologies, pilot
testing may be applicable to the development of reporting guidelines.
Although we used systematic review methods to identify and select
papers, we acknowledge that some may have been missed, however any
impact from missed papers is likely to be limited.
6. Conclusion
The reporting of guidelines while including details of their devel-
opment, frequently fail to explicitly identify validation activities even
when they have clearly been undertaken. While this may appear to be a
semantic or even pedantic issue, emphasising that reporting guidelines
have been validated could help encourage authors to use the guidelines,
publishers and journals to mandate checklist submission with manu-
scripts, and peer reviewers to monitor accuracy of completion. An im-
provement in any, and ideally all, of these approaches would be
Table 1
Types of validation method used for PROMS development.
Validation Method Number of studies
using methoda
Number of studies using
single method only
Comparison to similar
measures
n= 23 n=5
Delphi consensus n= 1 n=1
Expert opinion n= 1 n=0
Focus groups n= 3 n=0
Interviews n= 7 n=3
Statistical testing n= 56 n=31
a Note some studies used multiple methods, therefore total n exceeds number
of papers included.
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beneﬁcial in promoting high quality research and reducing research
waste.
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Table 2
Combinations of validation methods used for PROMS development.
Validation Method Number of studies using method
Statistical testing plus comparison to similar measures n= 17
Statistical testing plus expert opinion n= 1
Statistical testing plus focus groups n= 1
Statistical testing plus interviews n= 2
Statistical testing plus comparison to similar measures plus focus groups n= 1
Statistical testing plus comparison to similar measures plus interviews n= 1
Statistical testing plus focus groups plus interviews n= 1
Table 3
Validation methods used in reporting guidelines for main study types.
Research Type Key Guideline Validation Methods
RCT CONSORT [12] - Stakeholder meeting
- Evidence synthesis
- Stakeholder review of draft
Observational Studies STROBE [13] - Literature search
- Stakeholder meeting
- Stakeholder review of drafts
(following iterative review)
- Peer review
Case Reports
Systematic Review PRISMA [14] - Literature search
- Survey of peers using systematic
review methodology
- Stakeholder meeting and review of
drafts
Qualitative COREQ [4] - Literature search
- Consensus discussions between
authors
ENTREQ [15] - Literature review
- Inductive generation of items
- Pilot testing
- Iterative review
- Pilot testing
Diagnostic/Prognostic STARD (2015)
[16]
- Literature review
- Survey
- Stakeholder meeting
- Pilot testing
TRIPOD [17] - Stakeholder meeting
- Literature search
- Survey
- Stakeholder meeting and review of
drafts
Economic Evaluation CHEERS [18] - Systematic review
- Survey of collaborators
- Modiﬁed Delphi panel (2 rounds)
Protocols SPIRIT [19] - Delphi consensus survey
- Evidence synthesis
- Stakeholder meetings
- Pilot testing
PRISMA-P [20] - Mapping of existing guidelines
- Stakeholder meeting and review of
drafts
- Delphi consensus (from
PROSPERO)
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